Liver health study for children & young adults with Down syndrome
Part of Brain & nervous system, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how eating patterns and body composition relate to fatty liver in children and young adults with Trisomy 21 (Down syndrome) or other genetic intellectual disabilities. It may help understand who is at risk and how to prevent liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 22 years old.
- You have Trisomy 21 (Down syndrome) or another genetic cause of intellectual disability.
- Your body mass index (BMI) is between 17 and 40.
- You do not have a known liver disease.
- You are not taking medicines like Ozempic or Wegovy (GLP-1 drugs) that change body composition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood vessels work in adults with Down syndrome compared to those without Down syndrome. It aims to understand heart health better and may help improve future care.
This study looks at whether simple blood tests and scans can find fatty liver disease in children who are overweight or have extra belly fat, without needing a needle biopsy. If it works, it could help diagnose and monitor liver health more easily.
This study looks at how gums and inflammation work in children with Down syndrome by collecting and analyzing biological samples. It may help researchers understand gum health differences and improve future care.
This study uses MRI scans to look at the livers of children with obesity, to find early signs of liver problems. It may help doctors understand how to protect the liver in children.
This is a registry study collecting information about children and teens with fatty liver disease that isn’t caused by alcohol. It aims to better understand this condition and may help future research and treatments.
This study tests whether a medicine called empagliflozin (a type of SGLT2 inhibitor) can help treat non-alcoholic fatty liver disease in adolescents with obesity. It aims to see if the drug can reduce fat in the liver and improve liver health.
Hear when a new Obesity Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.